ArticleBMC microbiology2019
Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus casei in the murine model of vulvovaginal candidiasis.
Article in BMC microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 52 citations in OpenAlex.
- Exploration of endogenous signal peptides and tandem linkage strategies for enhanced heterologous protein secretion inSynthetic and systems biotechnology · 2026Article
- Retracing the origin and evolution of a cryptic antimicrobial peptide within mammalian lactoferrin.PLoS biology · 2026Article
- The Role of Lactoferrin in CombatingMolecules (Basel, Switzerland) · 2025Review
- Green synthesis of a lactoferrin-infused silver nanoparticle gel for enhanced wound healing.Scientific reports · 2025Article
- Nomadic Lactobacilli as cell factory for antibiofilm therapy.Frontiers in cellular and infection microbiology · 2025Review
- Lactoferrin as a Versatile Agent in Nanoparticle Applications: From Therapeutics to Agriculture.Nanomaterials (Basel, Switzerland) · 2024Review
- Review
- Therapeutic effects of orally administration of viable and inactivated probiotic strains against murine urinary tract infection.Journal of food and drug analysis · 2023Review
- Probiotics and Their Bioproducts: A Promising Approach for Targeting Methicillin-ResistantMicroorganisms · 2023Review
- Bovine Lactoferrin-Loaded Plasmonic Magnetoliposomes for Antifungal Therapeutic Applications.Pharmaceutics · 2023Article
- Review
- Newly Discovered Antimicrobial Peptide ScyampcinAntimicrobial agents and chemotherapy · 2023Article
- Use of probiotic lactobacilli in the treatment of vaginal infections:Frontiers in cellular and infection microbiology · 2023Review
- The role of microbiomes in gastrointestinal cancers: new insights.Frontiers in oncology · 2023Review
- Inhibitory effect of lactobacilli supernatants on biofilm and filamentation ofFrontiers in microbiology · 2023Article
- Lactoferrin versus Long-Acting Penicillin in Reducing Elevated Anti-Streptolysin O Titer in Cases of Tonsillopharyngitis.Infection and drug resistance · 2022Article
- The Antibiofilm Role of Biotics Family in Vaginal Fungal Infections.Frontiers in microbiology · 2022Review
- Antimicrobial and Prebiotic Activity of Lactoferrin in the Female Reproductive Tract: A Comprehensive Review.Biomedicines · 2021Review
- Perspectives on Existing and Novel Alternative Intravaginal Probiotic Delivery Methods in the Context of Bacterial Vaginosis Infection.The AAPS journal · 2021Review
- In Vivo Efficacy ofJournal of fungi (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVulvovaginal candidiasis (VVC) is a common vaginitis caused by Candida species,a frequently recurring condition. Fungal azole-resistant strains with azole-resistance have developed for long and wide explosion to the first-line antifungal azole agent. Bovine lactoferrin (BLF) is a protein from transferrin family secreted by the bovine mammary tissue. Its various biological functions are well known, especially the pronounced antifungal activity.
resultsIn the current study, we constructed a Lactobacillus casei strain (L.casei/pPG612.1-BLF), which secreted BLF encoded by a mature secretion vector plasmid pPG612.1, and evaluated its antifungal activity in vitro and in vivo. In a two-layer agar plate in vitro assay, the number of C. albicans CFUs decreased and the average colony size shrunk upon exposure to L. casei/pPG612.1-BLF. In a murine VVC model, the infection burden of mice intra-vaginally pre-inoculated with L. casei/pPG612.1-BLF was lower than in control groups. Furthermore, the infection burden in mice with VVC was reduced when the animals were continually given L. casei/pPG612.1-BLF as a topical treatment for 5 days.
conclusionCombined, these results suggested that the L. casei/pPG612.1-BLF strain is a promising preventative and therapeutic anti-VVC agent, highlighting the possibility of employing the probiotic L. casei as a vehicle for biotherapy in the female genital tract and exploiting the natural antibiotic antimicrobial peptides for other applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.